ClinicalTrials.gg

Program

Sulbactam

Also written as “Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)”, “Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)” and “Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)”.

Its studies are mostly in Respiratory Tract Infections · Communicable Diseases · Gonorrhea · Pneumonia, Bacterial · Pneumonia, led by 4 companies.

Furthest: phase 4, since Dec 19, 20127 company-led studies, 1 open or runningNext primary completion: May 5, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Xiangbei Welman Pharmaceutical30 open or runningphase 4since Dec 19, 2012Dec 19, 2012none ahead
Pfizer20 open or runningphase 4since Aug 25, 2005Aug 25, 2005none ahead
Innoviva Specialty Therapeutics11 open or runningphase 1since Jan 16, 2025Jan 16, 2025May 5, 2028phase 1 · NCT06801223
Yung Shin Pharm. Ind.10 open or runningphase 4since Dec 8, 2022Dec 8, 2022none ahead

Also a collaborator on its studies: entasis-therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2005First study: phase 4 study in PneumoniaNew to PfizerPfizer · NCT00137007 · 151 enrolled
  2. Aug 16, 2010Phase 3 study in Pneumonia, BacterialPfizer · NCT01189487 · 47 enrolled · Japan
  3. Dec 19, 2012Xiangbei Welman Pharmaceutical's first study: phase 4 study in Respiratory Tract InfectionsNew to Xiangbei Welman PharmaceuticalXiangbei Welman Pharmaceutical · NCT01760109 · 2,000 enrolled · China
  4. Aug 22, 2019Phase 4 study in Respiratory Tract InfectionsXiangbei Welman Pharmaceutical · NCT04066621 · 30 enrolled
  5. Dec 11, 2019Phase 4 study in GonorrheaXiangbei Welman Pharmaceutical · NCT04202068 · 113 enrolled
  6. Dec 8, 2022Yung Shin Pharm. Ind.'s first study: phase 4 study in Communicable DiseasesNew to Yung Shin Pharm. Ind.Yung Shin Pharm. Ind. · NCT05654090 · 14 enrolled · Taiwan
  7. Jan 16, 2025Innoviva Specialty Therapeutics's first study: phase 1 study in Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)New to Innoviva Specialty TherapeuticsInnoviva Specialty Therapeutics · NCT06801223 · 48 planned · United States

Ahead

  1. May 5, 2028Primary completion: phase 1 study in Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)Innoviva Specialty Therapeutics · NCT06801223

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial beta-lactamase TEM inhibitor”ChEMBL 37, by rule

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06801223Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC) · United States1RecruitingInnoviva Specialty TherapeuticsMay 5, 202848
NCT05654090Communicable Diseases · Taiwan4UNKNOWNYung Shin Pharm. Ind.Nov 18, 202214
NCT04202068Gonorrhea4CompletedXiangbei Welman PharmaceuticalMay 3, 2016113
NCT04066621Respiratory Tract Infections4CompletedXiangbei Welman PharmaceuticalJun 11, 201630
NCT01760109Respiratory Tract Infections · China4CompletedXiangbei Welman PharmaceuticalJun 20162,000
NCT01189487Pneumonia, Bacterial · Japan3CompletedPfizerApr 201147
NCT00137007Pneumonia4CompletedPfizer151

How it is read

Names in the registry

  • “Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours)”, 1 entry
  • “Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 8 hours)”, 1 entry
  • “Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 8 hours)”, 1 entry
  • “Sulbactam 20mg/kg-Durlobactam 20mg/kg (Every 12 hours)”, 1 entry
  • “cefoperazone sodium and sulbactam sodium”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.